Article
Version 1
Preserved in Portico This version is not peer-reviewed
Analysis of Potential Biomarkers in Frontal Temporal Dementia: A Bioinformatics Approach
Version 1
: Received: 7 August 2023 / Approved: 8 August 2023 / Online: 9 August 2023 (09:04:32 CEST)
A peer-reviewed article of this Preprint also exists.
Momin, I.D.; Rigler, J.; Chitrala, K.N. Analysis of Potential Biomarkers in Frontal Temporal Dementia: A Bioinformatics Approach. Int. J. Mol. Sci. 2023, 24, 14910. Momin, I.D.; Rigler, J.; Chitrala, K.N. Analysis of Potential Biomarkers in Frontal Temporal Dementia: A Bioinformatics Approach. Int. J. Mol. Sci. 2023, 24, 14910.
Abstract
Frontal Temporal Dementia (FTD) is a neurological disorder known to have less therapeutic options. So far only a few biomarkers are available for FTD that can be used as potential comorbidity targets. To this end, in the present study we aim to identify potential biomarkers or susceptible genes for FTD that show comorbidities with diseases such as COVID-19 and Breast Cancer. Gene expression Omnibus datasets containing FTD expression profiles from African American and white ethnicity background were included in our study. In FTD samples of GSE193391 dataset, we identified 305 DEGs with 168 genes being up-regulated and 137 genes being down-regulated. We conducted comorbidity analysis for COVID-19 and Breast cancer followed by analysis of potential drug interactions, pathogenicity, analysis of genetic variants and functional enrichment analysis. Resulting genes AKT3, GFAP, ADCYAP1R1, VDAC1, and C4A showed significant transcriptomic alterations in FTD and significant comorbidity status with COVID-19 and Breast cancer. Functional pathway analysis revealed that these comorbid genes were significantly enriched in the pathways such as glioma, JAK/STAT signaling, systematic lupus erythematosus, neurodegeneration-multiple diseases and neuroactive ligand-receptor interaction. Overall, from these results, we concluded that these genes could be recommended as potential therapeutic targets for the treatment of comorbidities in FTD.
Keywords
Frontal Temporal Dementia; Comorbidity; Breast cancer; COVID-19; Differential Gene expression analysis
Subject
Biology and Life Sciences, Biology and Biotechnology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment